Full Press Release Details
AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual
Global Investment Conference on September 5th
N.Y., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.
( AzurRx or the Company ), a company
specializing in the development of non-systemic, recombinant
therapies for gastrointestinal diseases, announced today the
Company will be making a company presentation during the Rodman and
Renshaw 20th Annual Global
Investment Conference in New York at the St. Regis
Hotel (Louis XVI B Room) on Wednesday, September 5th at 5:30 p.m.
Spoor, President and CEO, of AzurRx will provide an overview of the
Company's business during the live presentation and will be
available to participate in one-on-one meetings with investors who
are registered to attend the conference.
are an institutional investor, and would like to attend the
Company's presentation, please click on the following link
(www.rodmanevents.com) to
register for the Rodman & Renshaw conference. Once your
registration is confirmed, you will be prompted to log into the
conference website to request a one-on-one meeting with the
presentation will be webcast live. To access the webcast,
please visit www.rodmanevents.com.
The webcast replay will remain available for 90 days following the
About AzurRx BioPharma, Inc.:
BioPharma, Inc. (NASDAQ:AZRX) is engaged in the
research and development of non-systemic biologics for the
treatment of patients with gastrointestinal disorders. MS1819
recombinant lipase for exocrine pancreatic insufficiency is the
Company's lead development program, and additional early stage
research is being conducted for the prevention of hospital-acquired
infections. The Company is headquartered in Brooklyn, NY, with
scientific operations based in Langlade, France. Additional
information on the company can be found at www.azurrx.com.
Forward-Looking Statements:
press release contains forward-looking statements within the
meaning of the Private Securities Litigations Reform Act of 1995.
Such statements include, but are not limited to, any statements
relating to our product development programs and any other
statements that are not historical facts. Such statements involve
risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors
that could cause actual results to differ materially from
management's current expectations include those risks and
uncertainties relating to the development and testing of our drug
candidates, the regulatory approval process, our ability to secure
additional financing, the protection of our patent and intellectual
property, the success of strategic agreements and relationships,
and the potential commercialization of any product we may
successfully develop. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
Parkside Avenue, Suite 304
BioPharma IR contact:
Vitzthum, Managing Director
West 55th Street - Suite 16B